Riskpilot← Back to searchSign inGet full accessAgteria Biotech AB
ABActiveOrg 5594582594Birger Jarlsgatan 57 CResearch and experimental development on natural sciences and engineering · NACE 7210Est. 20231-4 employees
Revenue 2024
SEK 0
EBITDA margin
—
Equity ratio
64.4%
Financial strength
Net profit 2024
SEK -7,3M
| Revenue | SEK 0 | — |
| EBITDA | SEK -7,6M | — |
| Net profit | SEK -7,3M | — |
| Total assets | SEK 13,2M | — |
| Equity | SEK 8,5M | — |
| Employees | — | — |
Legal name
Agteria Biotech AB
Org number
5594582594
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
21 november 2023
Share capital
SEK 33 171
Employees
1-4
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas två i förening av ledamöterna Dessutom har verkställande direktören rätt att teckna firman beträffande löpande förvaltningsåtgärder
Company purpose
Bolaget ska bedriva forskning och utveckling utav organiska molekyler i syfte att reducera växthusgaser från olika branscher samt därmed förenlig verksamhet.
Address
Birger Jarlsgatan 57 C
Email
martin@agteria.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2024 |
|---|---|
| Revenue | 0 |
| Staff expenses | −1 385 |
| EBITDA | −7 574 |
| Depreciation & amort. | −4 |
| EBIT | −7 578 |
| Net financials | 243 |
| Profit before tax | −7 335 |
| Tax | — |
| Net profit | −7 335 |
| Item | 2024 |
|---|---|
| Total assets | 13 240 |
| Equity | 8 521 |
| Long-term debt | — |
| Short-term debt | 4 718 |
| Total debt | 4 718 |
EBITDA margin
-757388200.0%
This company
15.8%
Market median
-4793596303% vs market
20242024
Equity ratio
64.4%
This company
38.2%
Market median
+69% vs market
20242024
Return on equity
-86.1%
This company
18.4%
Market median
-568% vs market
20242024
Net profit margin
-733469700.0%
This company
8.1%
Market median
-9055181581% vs market
20242024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20242024
Debt / equity
0.55×
This company
0.62×
Market median
+11% vs market
20242024
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
RA Auditor Substitute | Auditor Substitute | 2025 |
MP Chief Executive Officer | Chief Executive Officer | 2023 |
| Audit | 2025 | |
| Name | Role | Member since |
|---|---|---|
| Current (8) | ||
| Chairman | 2024 | |
| Deputy Board Member | 2026 | |
| Board of Directors | 2025 | |
| Deputy Board Member | 2025 | |
| Deputy Board Member | 2026 | |
| Board of Directors | 2025 | |
| Board of Directors | 2026 | |
| Board of Directors | 2024 | |
| Former (3) | ||
| Chairman | 2023 – 2024 | |
| Board of Directors | 2023 – 2024 | |
| Board of Directors | 2024 – 2024 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Agteria Biotech AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Rickard Anders Beergrehn | Auditor Substitute | 0 companies |
| Martin Peter Harald Blomberg | Chief Executive Officer | 0 companies |
| Marcus Hans Eric Jönsson Vallas | Audit | 0 companies |
| Erik Engellau-Nilsson | Chairman | 0 companies |
| Björn Andreas Lindh | Chairman | 0 companies |
| Kirsty Jean Bellringer | Deputy Board Member | 0 companies |
| Sankhamala Valroy | Board of Directors | 0 companies |
| Patrik Georg Andlin Sobocki | Deputy Board Member | 0 companies |
| Tobias Elmquist | Deputy Board Member | 0 companies |
| Jörgen Lenz | Board of Directors | 0 companies |
| David William John Macdonald | Board of Directors | 0 companies |
| Jakob Martin Regberg | Board of Directors | 0 companies |
| Jean Fredrik Jung Abbou | Board of Directors | 0 companies |
| Anna Sofia Graflund | Board of Directors | 0 companies |